CN1245180C - Hypertension treating traditional Chinese medicine preparation and its preparing process - Google Patents
Hypertension treating traditional Chinese medicine preparation and its preparing process Download PDFInfo
- Publication number
- CN1245180C CN1245180C CN 200310105398 CN200310105398A CN1245180C CN 1245180 C CN1245180 C CN 1245180C CN 200310105398 CN200310105398 CN 200310105398 CN 200310105398 A CN200310105398 A CN 200310105398A CN 1245180 C CN1245180 C CN 1245180C
- Authority
- CN
- China
- Prior art keywords
- preparation
- chinese medicine
- add
- ethanol
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims description 7
- 230000008569 process Effects 0.000 title description 3
- 239000007788 liquid Substances 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 33
- 239000008187 granular material Substances 0.000 claims abstract description 11
- 239000007924 injection Substances 0.000 claims abstract description 9
- 238000002347 injection Methods 0.000 claims abstract description 9
- 239000003826 tablet Substances 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 239000006187 pill Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- 239000000243 solution Substances 0.000 claims description 31
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 claims description 30
- 239000000706 filtrate Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 claims description 15
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 claims description 15
- -1 filtered Substances 0.000 claims description 14
- 230000001631 hypertensive effect Effects 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- 238000004064 recycling Methods 0.000 claims description 11
- 235000008504 concentrate Nutrition 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- 241000345998 Calamus manan Species 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 5
- 238000002481 ethanol extraction Methods 0.000 claims description 5
- 235000012950 rattan cane Nutrition 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 229960001375 lactose Drugs 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 230000036772 blood pressure Effects 0.000 abstract description 12
- 208000024891 symptom Diseases 0.000 abstract description 12
- 239000002552 dosage form Substances 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 241000196324 Embryophyta Species 0.000 abstract 1
- 244000020551 Helianthus annuus Species 0.000 abstract 1
- 235000003222 Helianthus annuus Nutrition 0.000 abstract 1
- 244000179560 Prunella vulgaris Species 0.000 abstract 1
- 244000081822 Uncaria gambir Species 0.000 abstract 1
- 235000005272 common selfheal Nutrition 0.000 abstract 1
- 241000411851 herbal medicine Species 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000002173 dizziness Diseases 0.000 description 7
- 239000000284 extract Substances 0.000 description 6
- 230000001077 hypotensive effect Effects 0.000 description 6
- 230000001376 precipitating effect Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 206010047513 Vision blurred Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 206010040007 Sense of oppression Diseases 0.000 description 2
- 241001601725 Sthenias Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 241000233788 Arecaceae Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- LFZDEAVRTJKYAF-UHFFFAOYSA-L barium(2+) 2-[(2-hydroxynaphthalen-1-yl)diazenyl]naphthalene-1-sulfonate Chemical compound [Ba+2].C1=CC=CC2=C(S([O-])(=O)=O)C(N=NC3=C4C=CC=CC4=CC=C3O)=CC=C21.C1=CC=CC2=C(S([O-])(=O)=O)C(N=NC3=C4C=CC=CC4=CC=C3O)=CC=C21 LFZDEAVRTJKYAF-UHFFFAOYSA-L 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
- 239000009874 shenqi Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Abstract
The present invention relates to a Chinese medicine preparation for treating high blood pressure, which is characterized in that the preparation is composed of cortex moutan radics, common selfheal fruit-spike, sunflower leaf, gambir plant, radix puerariae and other Chinese herbal medicines. The preparation can be prepared into granules, tablets, capsules, oral medicinal liquids, injections, dripping pills and other dosage forms; the preparation has the effects of suppressing hyperactive liver, subsiding yang, clearing away heat and promoting blood circulation; the clinical treatment of 26 cases show that the total effective rate of blood pressure lowering is 84.6%, and the total effective rate in the aspect of single item symptom improvement in Chinese medicine is 96.2%.
Description
The invention belongs to field of traditional Chinese, relate to hypertensive preparation of a kind of treatment and preparation method thereof, its dosage form comprises tablet, capsule, granule, oral liquid, syrup, injection, drop pill and other dosage forms.
China is from annual New Development hypertensive patient more than 100 ten thousand 50～seventies of 20th century, and to annual New Development more than 300 ten thousand 80～nineties, number of patients has exceeded 100,000,000, and the trend of aggravation is arranged.Essential hypertension is not only one of common cardiovascular disease, and be apoplexy, coronary heart disease, the important risk factor of renal failure and retinopathy, has the prevalence height, awareness is low, the characteristics that disability rate is high, active and effective treatment hypertension purpose not only is controlling blood pressure, prior incidence rate and the mortality rate that also is to reduce the cardiovascular and cerebrovascular vessel intercurrent disease, so, control hypertension is as effective formulation of first grade of preventive measures, no matter for hyperpietic's happy family life, for the heavy medical treatment of country is born, all be a very significant thing still.
The present invention is just at hypertension, card belongs to the hyperactivity of YANG due to deficiency of YIN person and establishes, have suppressing the hyperactive liver and subsiding YANG, the effect of heat clearing and blood circulation promoting, dizzy, the headache that can be used for that hypertension causes, the soreness of waist, knee joint are soft, dysphoria with feverish sensation in the chest palms and soles, cardiopalmus, insomnia, tinnitus, forgetful, the few tongue of red tongue, stringy and thready pulse and number person.By clinical observation, blood pressure lowering total effective rate of the present invention is 84.6%, always effectively is 96.2% improving aspect the traditional Chinese medical science individual event symptom, and this shows that the present invention in effective blood pressure lowering, also can obviously improve symptom, and not find untoward reaction, and clinical effectiveness is satisfied.At present, clinically to evident in efficacy, safety is good, and Chinese medicine preparation easy to use is still for being badly in need of.By after the present invention and the hypertensive similar medicine contrast of treatment, we think that curative effect of the present invention is reliable, and have one's own knack on prescription medicine, are the crystallizations of clinical experience for many years.Therefore, exploitation of the present invention is expected to the Chinese medicine preparation that provides a safety, desirable blood pressure lowering effective, cheap, easy to use for clinical, is expected to obtain better economic, social benefit after applying.
The purpose of this invention is to provide a kind of Chinese medicine preparation that hypertension has obvious curative effects for the treatment of.
Technical scheme of the present invention is: the hypertensive Chinese medicine preparation of a kind of treatment is characterized in that by suppressing the hyperactive liver and subsiding YANG the Chinese prescription of heat clearing and blood circulation promoting forms, comprise Ramulus Uncariae Cum Uncis (10～38%), Cortex Moutan (10～35%), Spica Prunellae (5～25%), Folium Helianthi (5～32%), Radix Puerariae (4～30%).
The present invention treats hypertensive Chinese medicine preparation, it is characterized in that: the Chinese medicine of respectively distinguishing the flavor of among the present invention is extracted, and the extracting solution concentrating under reduced pressure becomes concentrated solution; After concentrated solution is dried to extract dry powder by distinct methods,, can be made into solid preparations such as granule, capsule, tablet by adding different auxiliary material respectively; Also can will add an amount of distilled water in the concentrated solution, after water precipitating filters, add adjuvant and antiseptic and make liquid preparations such as oral liquid and injection.Add different auxiliary material in the different dosage form of the present invention, do not influence clinical effectiveness of the present invention, these adjuvants comprise starch, microcrystalline Cellulose, magnesium stearate, dextrin, lactose, sucrose, antiseptic, Polyethylene Glycol etc.Therefore the present invention can satisfy the requirement of numerous hyperpietics to different dosage form.
The Pharmacodynamic test of active extract result of this preparation shows: the doses single-dose has tangible hypotensive activity to anesthetized dog; Single-dose has good acute hypotensive effect to clear-headed spontaneous hypertensive rat and renal hypertensive rat, and especially the hypotensive effect to renal hypertensive rat is bigger, amount-result relation is obvious; Long term administration in continuous 15～21 days, clear-headed spontaneous hypertensive rat and kidney high pressure rat also had the good curing hypotensive effect, and the efficacy of antihypertensive treatment of keeping that a few days is arranged after the drug withdrawal is especially bigger to the renal hypertensive rat hypotensive effect, amount-result relation is obvious.Radix Semiaquilegiae blood pressure lowering administration in continuous 15 days can make the nervous element of renal hypertensive rat blood medium vessels, concentration of cortisol obviously descend.The Radix Semiaquilegiae blood pressure lowering has tangible influence to the anesthetized dog hemodynamic index, left indoor pressure, left chamber EDP, ejection time, total oxygen consumption index and blood vessel total peripheral resistance are descended, and can increase coronary flow, increase arterial oxygen content.Acute toxicity test of the present invention and long term toxicity test result show and do not see overt toxicity reaction.
Use tablet of the present invention clinically 26 routine liver-Yang sthenia type hyperpietics are carried out clinical observation, and compare with QUANTIANMA JIAONANG.The result shows: test blood blood pressure lowering total effective rate is 84.6%, and matched group blood pressure lowering total effective rate is 65%, two group and has compared bright significant difference (P＜0.05) that this shows that the Radix Semiaquilegiae hypertension pill has good hypotensive effect; Improving aspect the traditional Chinese medical science individual event symptom, the test group total effective rate is 96.2%, and matched group always has rate to be 70%, two group to have compared significant difference (P＜0.05), and this shows that the Radix Semiaquilegiae hypertension pill in effective blood pressure lowering, also can obviously improve symptom.Also observed the influence of tablet of the present invention in the clinical trial process simultaneously, found that treatment front and back Non Apparent Abnormality changes safety indexes such as blood, routine urinalysis, liver, renal functioies.Clinical taking also do not report in the process that gastrointestinal tract and other untoward reaction are arranged, and illustrates that the present invention takes safety.
Traditional Chinese medical science efficacy analysis of the present invention:
1 materials and methods
1.1 physical data diagnostic criteria and standard by stages: hyperpietic diagnostic criteria and grade scale are all with reference to the diagnostic criteria of WHO in 1999 about hypertension
[1], tcm diagnosis standard reference new Chinese medicine is treated the liver-Yang sthenia type in the dizzy clinical research guideline.46 routine patients all derive from the outpatient service of intracardiac section of Hospital Attached to Shandong Chinese Medical Univ., are divided into treatment group and matched group at random.Test group 26 examples, wherein male 12 examples, women 14 examples, 55.14 ± 11.45 years old mean age, average course of disease 10.87 ± 7.13 years; Matched group 20 examples, wherein male 11 examples, women 9 examples, mean age 55.97 ± 10.85, average course of disease 11.46 ± 6.98 years.Two groups of pressure values before sex, age, the course of disease, treatment, the traditional Chinese medical science individual event symptom aspect such as relatively all do not have significant difference (P＜0.05).
1.2 Therapeutic Method test group tablet of the present invention, each 4, every day 3 times.Matched group is taken QUANTIANMA JIAONANG (Guizhou Shenqi Pharmaceutical Co., Ltd's production), every day 3 times, and each 4 balls, two groups is a course of treatment with 4 weeks all, after finishing for 1 course of treatment, the statistics curative effect.
1.3 observation item is observed two groups of blood pressure level and dizzy, headache, dizziness and distending sensation of the head, stiffness of the neck, flushing conjunctival congestion, being irritable and getting angry easily, nervous, feeling of oppression and pain in the chest, insomnia, tinnitus, blurred vision and constipation red 12 symptoms of urinating before and after the treatment and is showed.
1.4 efficacy assessment standard efficacy of antihypertensive treatment evaluation criteria: the standard of formulating with reference to national cardiovascular epidemiology in 1979 and crowd prevention and treatment forum; Tcm symptom total effects criterion: evaluate with reference to the regulation in " the new Chinese medicine clinical research guideline " of Ministry of Public Health promulgation in 1993.
1.5 statistical procedures adopts Ridit to analyze and the t check is carried out statistical procedures to related data.
2 results
2.1 two groups of efficacy of antihypertensive treatment and blood pressure lowering amplitude relatively see Table 1～3.
Table 1 liang group efficacy of antihypertensive treatment relatively
| N | Produce effects | Effectively | Invalid | Total effective rate | |
| The test group matched group | 26 20 | 5 5 | 6 8 | 2 7 | 84.6％ 65％ |
Analyze through Ridit, P＜0.05, test group is better than matched group.
Table 2 liang group systolic pressure reduction amplitude is (kPa) relatively
| Before the treatment | After the treatment | |
| The test group matched group | 22.9±2.6 22.8±2.5 | 18.7±2.1 *# 12.1±1.2 |
*Expression and preceding relatively P＜0.01 of treatment,
#Expression is compared P＜0.01 with matched group.
Table 3 liang group diastolic pressure reduction amplitude is (kPa) relatively
| Before the treatment | After the treatment | |
| The test group matched group | 13.8±1.2 13.9±0.3 | 11.2±1.0 *# 12.1±1.2 |
*Expression and preceding relatively P＜0.01 of treatment,
#Expression is compared P＜0.01 with matched group.
As shown in Table 1, produce effects 5 examples in test group 26 examples, effective 6 examples, total effective rate is 84.6%, is better than matched group, two groups of curative effects are compared through the Ridit analysis significant difference (P＜0.05).Distinguish self more all utmost point significant difference (P＜0.01) by systolic pressure and diastolic pressure before and after table 2, the visible two groups of patient treatments of table 3.
2.2 the tcm symptom curative effect sees Table 4～5.Two groups of curative effects of treatment group as shown in Table 4 and matched group are compared, and analyzing through Ridit has significant difference (P＜0.05); As shown in Table 5, the treatment group except that " being irritable and getting angry easily " and " blurred vision ", all is better than matched group improving aspect the traditional Chinese medical science individual event symptom, has compared significant difference (P＜0.05 or P＜0.01) for two groups.
Table 4 liang group tcm symptom total effects relatively
| N | Recovery from illness | Produce effects | Effectively | Invalid | Total effective rate | |
| The test group matched group | 26 20 | 3 0 | 7 4 | 2 10 | 1 6 | 96.2％ 70％ |
Analyze through Ridit, P＜0.05, test group is better than matched group.
Table 5 liang group traditional Chinese medical science individual event symptom curative effect relatively
| Test group | Matched group | ||||||||||||
| N | Recovery from illness | Produce effects | Effectively | Invalid | Total effective rate | N | Recovery from illness | Produce effects | Effectively | Invalid | Total effective rate | P | |
| The constipation of the nervous feeling of oppression and pain in the chest insomnia of the strong flushing hot eyes being irritable and getting angry easily of dizziness and headache dizziness and distending sensation of the head neck tinnitus blurred vision is urinated red | 26 16 16 8 10 8 14 18 12 10 10 8 | 6 10 8 4 2 0 4 2 10 6 4 2 | 14 6 8 4 6 6 6 10 0 2 4 2 | 6 0 0 0 2 0 4 6 2 2 0 4 | 0 0 0 0 0 2 0 0 0 0 2 0 | 100％ 100％ 100％ 100％ 100％ 75％ 100％ 100％ 100％ 100％ 80％ 100％ | 17 19 12 15 13 7 4 10 5 4 9 7 | 1 2 1 1 1 1 0 3 0 0 1 0 | 2 2 1 2 1 1 1 0 0 0 2 2 | 10 8 6 8 6 2 2 4 2 1 3 1 | 4 7 4 4 5 3 1 3 3 3 3 4 | 76.5％ 63.2％ 66.7％ 73.3％ 61.5％ 57.1％ 75％ 70％ 40％ 25％ 66.7％ 42.9％ | ＜0.05 ＜0.05 ＜0.05 ＜0.05 ＜0.05 ＞0.05 ＜0.05 ＜0.05 ＜0.01 ＜0.01 ＞0.05 ＜0.01 |
Prescription of the present invention also can add other and have suppressing the hyperactive liver and subsiding YANG, the Chinese medicine of heat clearing and blood circulation promoting on the basis of above-mentioned five kinds of Chinese medicine.
Using method of the present invention: oral, every day three times, each 3～4 (or 4～6 capsules, or 1 bag of granule, or 1～2 oral liquid, or 10～20ml syrup, or drop pill 10～15).4 weeks were a course of treatment; Or every day 1 of injection injection liquid, 10 days is a course of treatment.
It below is the specific embodiment of the present invention.
Embodiment 1:
Hook taking rattan 1800g, Radix Puerariae 650g add 80% ethanol extraction secondary, and 2 hours for the first time, 1 hour for the second time, merge extractive liquid, filtered, filtrate recycling ethanol, and be condensed into the concentrated solution that relative density is 1.16～1.18 (60 ℃); Get Cortex Moutan 1300g again, the distillation paeonol; Medicinal residues and Spica Prunellae 700g decoct with water secondary, and each 1 hour, merge extractive liquid, filtered, and filtrate concentrates; Other gets Folium Helianthi 1000g and decocts with water secondary, each 1 hour, merge extractive liquid,, filter, filtrate concentrates, and gets above-mentioned Cortex Moutan, two kinds of concentrated solutions merging of Folium Helianthi, adding ethanol makes and contains the alcohol amount and reach 60%, cold preservation (2～2 ℃) 24 hours filters, and filtrate recycling ethanol also is condensed into the concentrated solution that relative density is 1.16～1.18 (60 ℃); Get above-mentioned two kinds of concentrated solutions, merge, continue to be condensed into thick paste, drying adds paeonol, pulverizes, and is the dried medicated powder of extraction of the present invention; Or get above-mentioned two kinds of concentrated solutions merging, and adding the 200ml distilled water and make dissolving, water precipitating (2～2 ℃) 24 hours filters, and adds paeonol, and filtrate is extraction medicinal liquid of the present invention.
Embodiment 2:
Hook taking rattan 1450g, Radix Puerariae 800g add 80% ethanol extraction secondary, and 2 hours for the first time, 1 hour for the second time, merge extractive liquid, filtered, filtrate recycling ethanol, and be condensed into the concentrated solution that relative density is 1.18～1.20 (60 ℃); Get Cortex Moutan 1700g again, the distillation paeonol; Medicinal residues and Spica Prunellae 500g decoct with water secondary, and each 1 hour, merge extractive liquid, filtered, and filtrate concentrates; Other gets Folium Helianthi 1600g, decoct with water secondary, each 1 hour, merge extractive liquid, filtered, filtrate concentrates, get two kinds of concentrated solutions of above-mentioned Cortex Moutan, Folium Helianthi and merge, add ethanol and make and contain the alcohol amount and reach 70%, cold preservation (2～2 ℃) 24 hours, filter, filtrate recycling ethanol also is condensed into the concentrated solution that relative density is 1.18～1.20 (60 ℃); Get above-mentioned two kinds of concentrated solutions and merge, continue to be condensed into thick paste, the reduced vacuum drying adds paeonol, pulverizes, and is the dried medicated powder of extraction of the present invention; Or get above-mentioned two kinds of concentrated solutions merging, and adding the 300ml distilled water and make dissolving, water precipitating (2～2 ℃) 24 hours filters, and adds paeonol, and filtrate is extraction medicinal liquid of the present invention.
Embodiment 3:
Hook taking rattan 1200g, Radix Puerariae 1000g add 70% ethanol extraction secondary, and 2 hours for the first time, 1 hour for the second time, merge extractive liquid, filtered, filtrate recycling ethanol, and be condensed into the concentrated solution that relative density is 1.20～1.22 (60 ℃); Get Cortex Moutan 2000g again, the distillation paeonol; Medicinal residues and Spica Prunellae 900g decoct with water secondary, and each 1 hour, merge extractive liquid, filtered, and filtrate concentrates; Other gets Folium Helianthi 1400g, decoct with water secondary, each 1 hour, merge extractive liquid, filtered, filtrate concentrates, get two kinds of concentrated solutions of above-mentioned Cortex Moutan, Folium Helianthi and merge, add ethanol and make and contain the alcohol amount and reach 50%, cold preservation (2～2 ℃) 24 hours, filter, filtrate recycling ethanol also is condensed into the concentrated solution that relative density is 1.20～1.24 (60 ℃); Get above-mentioned two kinds of concentrated solutions and merge, continue to be condensed into thick paste, spray drying adds paeonol, pulverizes, and is the dried medicated powder of extraction of the present invention; Or get above-mentioned two kinds of concentrated solutions merging, and adding the 500ml distilled water and make dissolving, water precipitating (2～2 ℃) 24 hours filters, and adds paeonol, and filtrate is extracting solution of the present invention.
Embodiment 4:
Hook taking rattan 1000g, Radix Puerariae 500g add 60% ethanol extraction secondary, and 2 hours for the first time, 1 hour for the second time, merge extractive liquid, filtered, filtrate recycling ethanol, and be condensed into the concentrated solution that relative density is 1.22～1.24 (60 ℃); Get Cortex Moutan 1500g again, the distillation paeonol; Medicinal residues and Spica Prunellae 1000g decoct with water secondary, and each 1 hour, merge extractive liquid, filtered, filtrate concentrates, and adds ethanol and makes and contain the alcohol amount and reach 60%, cold preservation (2～2 ℃) 24 hours, filter, filtrate recycling ethanol, and be condensed into the concentrated solution that relative density is 1.22～1.24 (60 ℃); Other gets Folium Helianthi 1800g, decocts with water secondary, and each 1 hour, merge extractive liquid,, filter, filtrate concentrates, and adds ethanol and makes and contain the alcohol amount and reach 60%, cold preservation (2～2 ℃) 24 hours, filter, filtrate recycling ethanol, and be condensed into the concentrated solution that relative density is 1.22～1.24 (60 ℃); Get above-mentioned three kinds of concentrated solutions and merge, continue to be condensed into thick paste, drying adds paeonol, pulverizes, and is the dried medicated powder of extraction of the present invention; Or get above-mentioned three kinds of concentrated solutions merging, and adding the 400ml distilled water and make dissolving, water precipitating (2～2 ℃) 24 hours filters, and adds paeonol, and filtrate is the present invention and extracts medicinal liquid.
Embodiment 5: capsule
With adding 125g starch in the dried medicated powder of any extraction in the various embodiments described above, mix, granulate, sieve, adorn 1000 capsules, be capsule of the present invention.
Embodiment 6: granule
Will be in the various embodiments described above any one extracts and adds lactose 100g in the dried medicated powder, and dextrin 400g granulates, and granulate sieves, and makes the 1000g granule, granule of the present invention.
Embodiment 7: tablet
To add 130g starch in the dried medicated powder of any extraction in the various embodiments described above, the 20g microcrystalline Cellulose, mixing is granulated, and oven dry is sieved, and adds the 1.5g magnesium stearate, and mixing is pressed into 1000, is tablet of the present invention.
Embodiment 8: oral liquid
Will be in the various embodiments described above any one extracts and adds 0.3% sodium benzoate in the medicinal liquid, the 400ml distilled water, detoxicating, the 1000ml oral liquid is made in fill, oral liquid of the present invention.
Embodiment 9: syrup
Will be in the various embodiments described above any one extracts and adds 0.3% sodium benzoate in the medicinal liquid, adds sucrose 300g, and xanthan gum 100g makes the 1000ml syrup, syrup of the present invention.
Embodiment 10: injection
In the dried medicated powder of any extraction in the foregoing description, add 400ml water for injection, water precipitating (0～-2 ℃) 48 hours, microporous filter membrane filters, and the 500ml injection is made in fill, is injection of the present invention.
Implement just 11: drop pill
To any one extract in the medicinal liquid in the foregoing description, be added among the Polyethylene Glycol of heating and melting-6000 800g, stirring and dissolving is dripped and is made the 1000g ball, is drop pill of the present invention.
According to prescription of the present invention, can also make the preparation of other dosage forms such as suspensoid.
Hypertension is commonly encountered diseases, the frequently-occurring disease of China.At present, China hyperpietic has exceeded 100,000,000, relates to several ten million families.The apoplexy, coronary heart disease, renal failure, the retinopathy that are caused by hypertension have become the modal disease of China, and fatality rate, disability rate are higher.The present invention has acted on ancient Chinese medicine doctor to the hypertension understanding of (traditional Chinese medical science claims " dizzy "), draws elite place wherein, thinks that one of the crucial pathogenesis of hypertension is excessive rising of liver-YANG, obstruction of collaterals by blood stasis, so be principle of treatment with suppressing the hyperactive liver and subsiding YANG, heat clearing and blood circulation promoting.Of the present invention distinguishing controlled the thinking pathogenesis that links closely, giving consideration to both the incidental and fundamental, inside and outside extensively treating; And the flavour of a drug refine, medicine letter power is special, is treatment hypertension excessive rising of liver-YANG, or double obstruction of collaterals by blood stasis person's good recipe.
Therefore development of the present invention is faced with vast market, is wherein containing great social benefit and huge economic benefit.
Claims (4)
1, the hypertensive Chinese medicine preparation of a kind of treatment is characterized in that described Chinese medicine preparation is to be extracted by following flavour of a drug to be prepared from Ramulus Uncariae Cum Uncis 10～38%, Cortex Moutan 10～35%, Spica Prunellae 5～32%, Folium Helianthi 5～28%, Radix Puerariae 4～30%.
2, the preparation method of the described Chinese medicine preparation extracting solution of claim 1, it is characterized in that: hook taking rattan, Radix Puerariae add 60～80% ethanol extraction secondary, 2 hours for the first time, 1 hour for the second time, merge extractive liquid,, filter, filtrate recycling ethanol also is condensed into the concentrated solution of relative density 1.16～1.25; Get Cortex Moutan distillation paeonol again; Medicinal residues and Spica Prunellae decoct with water secondary, and each 1 hour, merge extractive liquid, filtered, and filtrate concentrates; Other gets Folium Helianthi and decocts with water secondary, each 1 hour, merge extractive liquid, filtered, filtrate concentrates, get two kinds of concentrated solutions of above-mentioned Cortex Moutan and Folium Helianthi and merge, add ethanol, make to contain the alcohol amount and reach 50～70%, precipitate with ethanol, cold preservation 24 hours filters, filtrate recycling ethanol and to be condensed into relative density be 1.16～1.25 concentrated solution; Merge above-mentioned two kinds of concentrated solutions, continue to be condensed into thick paste, available distinct methods drying is pulverized, and adds paeonol, and mixing sieves, and is the dried medicated powder of extraction of the present invention; Or with above-mentioned two kinds of concentrated solutions merging, add 100～600ml distilled water and make dissolving, add paeonol, be extraction medicinal liquid of the present invention.
3, preparation method according to claim 2 is characterized in that: add one or more adjuvants in described extraction medicinal liquid, promptly can be made into granule, capsule, tablet, oral liquid, syrup, suspensoid, injection or drop pill.
4, preparation method according to claim 3 is characterized in that: described one or more adjuvants are: starch, dextrin, microcrystalline Cellulose, magnesium stearate, lactose, sucrose, xanthan gum, Polyethylene Glycol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310105398 CN1245180C (en) | 2003-11-07 | 2003-11-07 | Hypertension treating traditional Chinese medicine preparation and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310105398 CN1245180C (en) | 2003-11-07 | 2003-11-07 | Hypertension treating traditional Chinese medicine preparation and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1541681A CN1541681A (en) | 2004-11-03 |
| CN1245180C true CN1245180C (en) | 2006-03-15 |
Family
ID=34333726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310105398 Expired - Lifetime CN1245180C (en) | 2003-11-07 | 2003-11-07 | Hypertension treating traditional Chinese medicine preparation and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1245180C (en) |
-
2003
- 2003-11-07 CN CN 200310105398 patent/CN1245180C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1541681A (en) | 2004-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1321671C (en) | Chinese medicinal composition, its preparation method and use | |
| CN1824177A (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN103417846A (en) | Hypoglycemic traditional Chinese medicine composition and preparation method thereof | |
| CN102488838B (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN1596970A (en) | Traditional Chinese medicament for treating woman subhealthy faligue syndrome and its preparation method | |
| CN1814214A (en) | Chinese medicine composition for treating body thin and delicate coustitution, and preparing method | |
| CN110251591A (en) | A kind of pharmaceutical composition and its preparation method and application that aided blood pressure-lowering is hypoglycemic | |
| CN100377731C (en) | Chinese traditional medicine and its preparation method and use | |
| CN1817354A (en) | Injection of manchurian wildginge and astragalus root and its preparing method | |
| CN103211996B (en) | Preparation method of traditional Chinese medicine for treating diabetes mellitus | |
| CN1067901C (en) | Drug for curing migraine and its preparing method | |
| CN1245180C (en) | Hypertension treating traditional Chinese medicine preparation and its preparing process | |
| CN106581109A (en) | Cerebral thrombosis treating pharmaceutical composition | |
| CN102293855A (en) | Chinese medicinal composition for treating speech and kidney deficiency diabetic nephropathy, and preparation method and application thereof | |
| CN1264547C (en) | Preparation of Chinese traditional medicine for treating coronary heart disease and angina as well as preparation method | |
| CN1927289A (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and its preparation | |
| CN1182862C (en) | Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn | |
| CN1857531A (en) | Recipe, preparing process and application of Chinese medicine preparation for treating diabetic retinopathy | |
| CN1899385A (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN1182867C (en) | Preparation of Chinese herbal medicine for treating sequela of apoplexy and its preparing method | |
| CN1520859A (en) | Cerebrovascular and cardiovascular disease treating injection containing red-rooted salvia and safflower | |
| CN1245184C (en) | Insomnia treating traditional Chinese medicine preparation and its preparing process | |
| CN1261118C (en) | Medicine for treating arteriosclerosis and coronary heart disease and its preparation method | |
| CN1634541A (en) | Medicine for treating fatigue syndrome and preventing presenility, and preparation method thereof | |
| CN101632728B (en) | Application of Chinese medicinal composition in preparing medicament for protecting blood brain barrier |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Ling Inventor after: Ling Peixue Inventor after: Shang Lixia Inventor after: Shi Yanzeng Inventor before: Zhang Ling Inventor before: Ling Peixue Inventor before: Jing Rui Inventor before: Yu Shengmao Inventor before: Shang Lixia Inventor before: Shi Yanzeng |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHANG LING LING PEIXUE JING RUI YU SHENGMAO SHANG LIXIA SHI YANZENG TO: ZHANG LING LING PEIXUE SHANG LIXIA SHI YANZENG |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190109 Address after: 250101 989 Xinjie street, Ji'nan high tech Zone, Shandong Patentee after: SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES Address before: 250014 No. 264 Shanda Road, Jinan City, Shandong Province Patentee before: Ling Peixue |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060315 |
|
| CX01 | Expiry of patent term |